Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection
2022-06-26
عنوان الدراسة
Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection
داعم الدراسة
Janssen-Cilag International NV
دواء الدراسة
TMC435 (simeprevir)
رقم بروتوكول الدراسة
TMC435HPC3014
حالة الدراسة
Completed
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
3b
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.